Posner Christopher 4
4 · Cara Therapeutics, Inc. · Filed Feb 3, 2023
Insider Transaction Report
Form 4
Posner Christopher
DirectorPRESIDENT AND CEO
Transactions
- Sale
Common Stock
2023-02-02$11.80/sh−4,191$49,454→ 182,370 total
Footnotes (1)
- [F1]This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units reported in the Form 4 filed with the Securities and Exchange Commission on November 3, 2021 and does not represent a discretionary trade by the Reporting Person.